Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Am Vet Med Assoc ; 229(4): 542-8, 2006 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-16910854

RESUMO

OBJECTIVE: To determine outcome for dogs with nonresectable thyroid carcinomas treated with sodium iodide I 131 and identify factors associated with outcome. DESIGN: Retrospective case series. Animals-39 dogs. PROCEDURES: A definitive or presumptive diagnosis of thyroid tumor was made on the basis of cytologic or histologic examination, abnormal accumulation of sodium pertechnetate Tc 99m during scintigraphy, or both, and dogs were treated with sodium iodide I 131. Dogs with cervical thyroid tumors were evaluated 3 to 6 weeks after 131I therapy, and residual tumor was resected when feasible. RESULTS: Prior to 131I therapy, 32 dogs had a solitary mass and 7 had metastases; 21 were hyperthyroid, 16 were euthyroid, and 2 were hypothyroid. Median survival time for dogs with local or regional tumors (ie, stage II or III) was significantly longer (839 days) than median survival time for dogs with metastasis (366 days). Tumor site (cervical vs ectopic), dose of sodium iodide I 131, age, body weight, treatment (131I therapy alone vs 131I therapy followed by surgery), and serum T4 concentration prior to 131I therapy were not significantly associated with survival time. Three dogs died of radioiodine-associated myelosuppression within 3 months after treatment, but no specific factor associated with development of toxicosis was identified. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that 131I therapy may result in prolonged survival times in dogs with nonresectable thyroid tumors, regardless of serum thyroxine concentration prior to treatment. Dogs undergoing 131I therapy should be monitored for signs of bone marrow suppression.


Assuntos
Doenças do Cão/radioterapia , Radioisótopos do Iodo/uso terapêutico , Neoplasias da Glândula Tireoide/veterinária , Animais , Doenças do Cão/diagnóstico por imagem , Doenças do Cão/cirurgia , Cães , Feminino , Radioisótopos do Iodo/efeitos adversos , Masculino , Metástase Neoplásica , Cintilografia/métodos , Cintilografia/veterinária , Estudos Retrospectivos , Pertecnetato Tc 99m de Sódio , Análise de Sobrevida , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Neoplasias da Glândula Tireoide/radioterapia , Neoplasias da Glândula Tireoide/cirurgia , Tiroxina/sangue , Resultado do Tratamento
2.
J Am Vet Med Assoc ; 228(6): 898-901, 2006 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-16536702

RESUMO

OBJECTIVE: To determine the efficacy of strontium 90 beta irradiation in the management of cutaneous mast cell tumors (CMCTs) in cats. STUDY DESIGN: Retrospective case series. ANIMALS: 35 client-owned cats with CMCTs. PROCEDURE: Medical records of cats with CMCTs in which tumors were radiated by use of a strontium 90 ophthalmic applicator from 1992 to 2002 were reviewed. Cats were included if CMCT was diagnosed, there were no other sites of MCT involvement at the time of treatment, and records contained adequate follow-up information to permit retrospective assessment of local tumor control. RESULTS: 54 tumors in 35 cats were treated with a median dose of 135 Gy of strontium 90 beta irradiation, resulting in local tumor control in 53 of 54 (98%) tumors with a median follow-up time of 783 days after treatment. Median survival time was 1,075 days. Adverse effects of treatment appeared to be infrequent and of mild severity. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that strontium 90 beta irradiation resulted in long-term tumor control and should be considered an effective alternative to surgical resection in management of CMCTs in cats.


Assuntos
Doenças do Gato/radioterapia , Sarcoma de Mastócitos/veterinária , Neoplasias Cutâneas/veterinária , Radioisótopos de Estrôncio , Animais , Doenças do Gato/mortalidade , Gatos , Relação Dose-Resposta à Radiação , Feminino , Masculino , Sarcoma de Mastócitos/mortalidade , Sarcoma de Mastócitos/radioterapia , Estudos Retrospectivos , Neoplasias Cutâneas/mortalidade , Neoplasias Cutâneas/radioterapia , Radioisótopos de Estrôncio/efeitos adversos , Radioisótopos de Estrôncio/uso terapêutico , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento
3.
Vet Radiol Ultrasound ; 45(5): 466-70, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15487572

RESUMO

Gemcitabine (2',2'-difluorodeoxycytidine) was given intravenously twice weekly to 10 cats with oral squamous cell carcinoma and 15 dogs with nasal carcinoma undergoing radiotherapy as a radiosensitizing agent. The average total radiation dose was 50 Gy for dogs and 54 Gy for cats given Monday-Friday (planned dose of 54 and 57 Gy, respectively). Dogs received an average of five doses of gemcitabine beginning at 50 mg/m2, and cats received an average of five doses of gemcitabine beginning at 25 mg/m2. Twelve of 15 dogs and five of 10 cats required chemotherapy dose reduction or postponement because of hematologic or normal tissue toxicity. The results herein do not support the use of gemcitabine at the studied dose and schedule, as significant hematologic and local tissue toxicity was observed in the studied patients. Pharmacokinetic data are necessary to best define the efficacy and optimal dose and schedule of gemcitabine in combination with traditional radiotherapy.


Assuntos
Carcinoma de Células Escamosas/veterinária , Doenças do Gato/tratamento farmacológico , Desoxicitidina/análogos & derivados , Desoxicitidina/administração & dosagem , Doenças do Cão/tratamento farmacológico , Neoplasias de Cabeça e Pescoço/veterinária , Radiossensibilizantes/administração & dosagem , Animais , Carcinoma de Células Escamosas/tratamento farmacológico , Doenças do Gato/radioterapia , Gatos , Terapia Combinada , Desoxicitidina/efeitos adversos , Doenças do Cão/radioterapia , Cães , Feminino , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Masculino , Doses de Radiação , Radiossensibilizantes/efeitos adversos , Gencitabina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...